bluebird on track to submit MAA to EMA for LentiGlobin

bluebird bio Inc. (NASDAQ:BLUE) said it is on track to submit an MAA to EMA next half for its LentiGlobin BB305 to treat beta-thalassemia and reported additional data from three studies of the gene therapy. LentiGlobin BB305 comprises autologous CD34+ stem cells transduced ex vivo with a lentiviral vector delivering the human beta globin gene.

The company reported data from the Phase III Northstar-2 (HGB-207) and Phase I/II Northstar (HGB-204) studies to treat transfusion-dependent beta thalassemia patients with non-beta-0/beta-0 genotypes...